See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
RiverVest Venture Partners is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors. With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest accesses forward-thinking research and clinical expertise at leading institutions across the country to found and fund biopharma and medical device companies. The firm employs a dual strategy: founding and incubating very early-stage companies through its Archer Seed Fund, while also investing in select later-stage opportunities to diversify risk and maximize portfolio returns. RiverVest leads financings, builds strong investor syndicates, and provides scientific, operational, financial, and investment expertise to help entrepreneurs transform promising technologies into successful therapies.
Notable quotes
“Their promotions are a testament to their impact on furthering RiverVest's mission: to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.”
“I couldn't be more excited about the strength and cohesiveness of our team and the future of our firm.”
“It is incredibly rewarding to enable entrepreneurs to develop novel technologies and introduce them to the marketplace, potentially transforming the quality of life for patients around the world.”
Team
Niall O'Donnell, Ph.D.
Managing Director
Karen Spilizewski
Managing Director
Isaac Zike, Ph.D.
Managing Director
Pascal Krotee, Ph.D.
Principal
Andrew Kleiboeker
Associate
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Sparrow Pharmaceuticals | Series B | $95m | 2025-09-24 |
| Wugen | Series C | $115m | 2025-08-28 |
| Biolinq | Series C | $100m | 2025-04-22 |
| Glycomine | Series C | $115m | 2025-04-16 |
| Atalanta Therapeutics | Series B | $75m | 2025-01-28 |
| Alleviant Medical | Undisclosed | $90m | 2025-01-15 |
| Bluejay Therapeutics | Series C | $182m | 2024-05-09 |
| Engrail Therapeutics | Series B | $157m | 2024-03-19 |
| Mirum Pharmaceuticals | Series A | — | — |
| Avalyn Pharma | Series C | $175m | 2023-09-27 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Novo Holdings | 8 |
| OrbiMed | 5 |
| RA Capital Management | 5 |
| Forbion | 4 |
| Frazier Life Sciences | 3 |
| F-Prime Capital | 3 |
Fit check
Is RiverVest Venture Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit